Table 3. Combination Index values (CI) of triple combinations BRY:PNB:RMD.
| Cell type | ratio 2.5:2:1 | ratio 5:2:1 | ||||||
|---|---|---|---|---|---|---|---|---|
| EC50 | EC75 | EC90 | EC95 | EC50 | EC75 | EC90 | EC95 | |
| J89GFP | 0.76 ± 0.16 (++) | 0.57 ± 0.1 (+++) | 0.42 ± 0.07 (+++) | 0.35 ± 0.05 (+++) | 0.47 ± 0.10 (+++) | 0.35 ± 0.07 (+++) | 0.26 ± 0.05 (++++) | 0.22 ± 0.04 (++++) |
| THP89GFP | 4.39 ± 2.02 (−) | 1.92 ± 0.22 (−) | 0.69 ± 0.11 (+++) | 0.46 ± 0.1 (+++) | 1.52 ± 0.62 (−) | 0.84 ± 0.24 (++) | 0.52 ± 0.09 (+++) | 0.4 ± 0.06 (+++) |
CI calculated at the EC50, EC75, EC90 and EC95. CI < 0.9 indicates synergism; 0.9 < CI < 1.1 indicates additive effects, and CI > 1.1 indicates antagonism (−). Synergy level: ± indicates additive effects; 0.85 < CI < 0.9 + (slight synergism); 0.7 < CI < 0.85 ++ (moderate synergism); 0.3 < CI < 0.7 +++ (synergism); CI < 0.1 < 0.3 ++++ (potent synergism). Compound range concentration: BRY (12.5–50 nM), PNB (5–40 nM) and RMD (2.5–20 nM). Each experiment was performed in duplicate. Data are represented as the mean ± SD of at least three independent experiments. Abbreviations: CI, combination index; EC50, 50% effective concentration; EC75, 75% effective concentration; EC90, 90% effective concentration; EC95, 95% effective concentration; SD, standard deviation; BRY, bryostatin-1; PNB, panobinostat; RMD, romidepsin.